Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2025 Feb 25;64(2):102.
doi: 10.1007/s00394-025-03618-9.

The efficacy and safety of berberine in combination with cinnamon supplementation in patients with type 2 diabetes: a randomized clinical trial

Asieh Mansour #  1 , Sayed Mahmoud Sajjadi-Jazi #  1 , Hadis Gerami  1   2 , Atie Sadat Khorasanian  1   3 , Behnam Moalemzadeh  4 , Sara Karimi  5 , Nima Mohamadi Afrakoti  6 , Vahid Mofid  7 , Mohammad Reza Mohajeri-Tehrani  1 , Azita Hekmatdoost  8
Affiliations
Randomized Controlled Trial

The efficacy and safety of berberine in combination with cinnamon supplementation in patients with type 2 diabetes: a randomized clinical trial

Asieh Mansour et al. Eur J Nutr. .

Abstract

Background: Diabetes is a serious global health issue and increases the risk of several chronic diseases. However, if hyperglycemia and other metabolic abnormalities related to diabetes are controlled, fewer micro- and macrovascular complications may occur.

Objective: To investigate whether daily supplementation with berberine in combination with cinnamon could have effect on cardiometabolic risk factors, such as impaired glucose regulation, dyslipidemia, and hypertension in patients with diabetes.

Methods: Patients with type 2 diabetes were recruited to participate in a parallel, double-blind, placebo-controlled, randomized study. Participants were randomized into berberine in combination with cinnamon supplementation or placebo group. Participants were then asked to take a divided daily dose of 1200 mg berberine and 600 mg cinnamon or placebo for 12 weeks. ANCOVA was then performed to evaluate the differences between the two groups, controlling for the respective baseline values.

Results: At the end of study, fasting blood sugar (FBS) (P = 0.031) and hemoglobin A1C (HbA1c) (P = 0.013) were significantly lower in participants taking berberine plus cinnamon than those taking the placebo capsules. The results of the serum lipid profile also indicated a significant difference in the level of low density lipoprotein cholesterol (LDL-C) (P = 0.039), while no difference was observed in the levels of total cholesterol, high density lipoprotein cholesterol (HDL-C), and triglycerides between the study groups. In addition, there was no difference in other measured metabolic and anthropometric parameters between the two groups.

Conclusion: Twelve weeks of berberine plus cinnamon consumption reduced blood FBS, HbA1c and LDL-C concentration in patients with diabetes.

Keywords: Berberine; Cardiometabolic risk factors; Cinnamon; Supplementation; Type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

Declarations. Consent for publication: Not applicable. Competing interests: It should be emphasized that Dr. Vahid Mofid is an employee of Pajoohesh Gostran Taghzie asan® Company. Other authors have not conflicts of interest or financial ties to disclose.

References

    1. Yun J-S, Ko S-H (2021) Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes. Metabolism 123:154838 - PubMed
    1. Lima JE, Moreira NC, Sakamoto-Hojo ET (2022) Mechanisms underlying the pathophysiology of type 2 diabetes: from risk factors to oxidative stress, metabolic dysfunction, and hyperglycemia. Mutat Research/Genetic Toxicol Environ Mutagen 874:503437
    1. Ogurtsova K, Guariguata L, Barengo NC, Ruiz PL-D, Sacre JW, Karuranga S et al (2022) IDF Diabetes Atlas: global estimates of undiagnosed diabetes in adults for 2021. Diabetes Res Clin Pract 183:109118 - PubMed
    1. Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB et al (2022) IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract 183:109119 - PubMed
    1. Taylor SI, Yazdi ZS, Beitelshees AL (2021) Pharmacological treatment of hyperglycemia in type 2 diabetes. J Clin Investig.;131(2)

Publication types

LinkOut - more resources